ANTIBODIES, COMPOUNDS AND SCREENS FOR IDENTIFYING AND TREATING CACHEXIA OR PRE-CACHEXIA

(19)

(11)

EP 3 307 781 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	02.12.2020 Bulletin 2020/49

(45)	Mention of the grant of the patent:
	28.10.2020 Bulletin 2020/44

(21)	Application number: 16733251.9

(22)	Date of filing: 10.06.2016

(51)

International Patent Classification (IPC):

A61K 31/166^(2006.01)
A61P 43/00^(2006.01)
G01N 33/68^(2006.01)

A61K 31/426^(2006.01)
C07K 16/28^(2006.01)

(86)	International application number:
	PCT/US2016/037082

(87)	International publication number:
	WO 2016/201368 (15.12.2016 Gazette 2016/50)

(54)	ANTIBODIES, COMPOUNDS AND SCREENS FOR IDENTIFYING AND TREATING CACHEXIA OR PRE-CACHEXIA ANTIKÖRPER, VERBINDUNGEN UND TESTS ZUR IDENTIFIZIERUNG UND BEHANDLUNG VON KACHEXIE ODER PRÄKACHEXIE ANTICORPS, COMPOSÉS ET ÉCRANS PERMETTANT L'IDENTIFICATION ET LE TRAITEMENT LA CACHEXIE OU PRÉ-CACHEXIE

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

10.06.2015 US 201562173901 P
10.06.2015 US 201562173908 P
19.06.2015 US 201562182140 P
16.07.2015 US 201562193516 P

(43)	Date of publication of application:
	18.04.2018 Bulletin 2018/16

(60)	Divisional application:
	20196326.1

(73)	Proprietors:
	The Broad Institute, Inc. Cambridge, MA 02142 (US) Dana-Farber Cancer Institute, Inc. Boston, MA 02215 (US)

(72)	Inventors:
	THOMAS, David, K. Brookline, MA 02446 (US) GOLUB, Todd, R. Newtown, MA 02464 (US)

(74)	Representative: Plasseraud IP
	66, rue de la Chaussée d'Antin 75440 Paris Cedex 09 75440 Paris Cedex 09 (FR)

(56)

References cited: :

WO-A1-2010/019656
WO-A1-2015/085097

WO-A1-2011/042548
WO-A2-2007/109747

MORLEY JOHN E ET AL: "Cachexia: pathophysiology and clinical relevance", THE AMERICAN JOURNAL OF CLINICAL NUTRITION, AMERICAN SOCIETY FOR NUTRITION, US, vol. 83, no. 4, 1 April 2006 (2006-04-01), pages 735-743, XP007913220, ISSN: 0002-9165
SPARVERO LOUIS J ET AL: "RAGE (Receptor for Advanced Glycation Endproducts), RAGE Ligands, and their role in Cancer and Inflammation", JOURNAL OF TRANSLATIONAL MEDICINE, BIOMED CENTRAL, LONDON, GB, vol. 7, no. 1, 17 March 2009 (2009-03-17), page 17, XP021050751, ISSN: 1479-5876, DOI: 10.1186/1479-5876-7-17
LECLERC E ET AL: "Binding of S100 proteins to RAGE: An update", BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR CELL RESEARCH, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 1793, no. 6, 1 June 2009 (2009-06-01) , pages 993-1007, XP026151996, ISSN: 0167-4889, DOI: 10.1016/J.BBAMCR.2008.11.016 [retrieved on 2008-12-11]

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).